检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:陈秀兰[1] 李振 吴洁[1] 黄慧[1] 潘洁[1] CHEN Xiu-lan;LI Zhen;WU Jie(Wuhu Blood Center,Anhui 241000)
机构地区:[1]安徽省芜湖市中心血站,241000 [2]芜湖市第一人民医院
出 处:《临床输血与检验》2018年第1期47-50,共4页Journal of Clinical Transfusion and Laboratory Medicine
摘 要:目的分析比较科华、达安两套核酸筛查系统的核酸检测(nucleic acid testing,NAT)能力。方法运用科华、达安核酸系统对经过ELISA法检测合格的56 703例血液标本及卫生部临床检验中心(NCCL)室间质评核酸标本进行检测,对其有效拆分率和核酸阳性检出率进行统计分析。结果科华核酸筛查系统共检测31 497例,混检阳性pool数35个,经拆分阳性pool数23个,阳性标本为26例,有效拆分率、阳性检出率分别为65.71%、0.08%。达安系统共检测25 206例,混检阳性pool数58个,经拆分阳性pool数30个,阳性标本为34例,有效拆分率、标本阳性检出率分别为51.72%、0.135%。10例NCCL标本全部正确检出。结论科华、达安筛查系统均能在酶免阴性标本中检出核酸阳性标本,在检测能力上各有优势,均能较好的胜任日常的核酸检测工作。Objective To analyze and compare the detective ability of nucleic acid testing Kehua and Daan.Methods Kehua and Daan nucleic acidscreeningsystems were used to detect 56703 specimens after routine examination qualified and 10 copies of NCCL specimens which had passed the ELISA test beforehand.Statistical analysis was conducted on the effective split ratio and positive ratio of nucleic acid.Results Kehua nucleic acid screening system screened 31,497 specimens and 35 mixed specimens were determined to be positive,among which 23 pools were determined reactive by split testing.The number of reactive samples was 26.The effective split ratio was 65.71%.The positive ratio of specimens was 0.083%.25 206 specimens were detected by Daan system and 58 mixed specimens were determined to be positive,among which 30 were reactive by split testing,and the number of reactive samples was 34.The effective split ratio was 51.72%.The positive ratio of specimens was 0.135%.10 cases of NCCL specimens were correctly detected.Conclusion Kehua and Daan screening system shows their own advantages in detecting positive samples from ELISA negative.Both are well fit for routine nucleic acid testing.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145